US China Synergies Apollomics operates in the US and China with a multi-asset oncology pipeline, creating cross-border partnership and licensing opportunities to accelerate development and commercialization across Western and Eastern markets.

MET Collaboration The Phase 2 asset vebreltinib (c-Met inhibitor) presents a high-potential flagship for global co-development, licensing deals, or strategic partnerships with companies seeking MET pathway leadership.

Diversified Portfolio Three mechanism groups enable versatile combination strategies, offering opportunities to partner with firms in chemotherapy, immuno-oncology, and targeted therapies to create synergistic oncology regimens.

Clinical Stage Readiness With five clinical-stage candidates across twelve programs, there are multiple entry points for asset-specific licensing, milestone-based co-development deals, and research collaborations.

Financial Momentum Recent bridge financing and board updates indicate strategic flexibility; explore co-development financing, milestone-rich partnerships, or CRO/co-development arrangements to advance trials and de-risk investments.